COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Fundamental Risk Analysis including financial ratios, debt levels, liquidity, and sustainability metrics. Compare against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Fundamental Risk Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.

Debt-to-Equity Ratio

0.50

Decreased from previous period

Dangerously higher D/E above 1.5x 3088.T's 0.24. Jim Chanos would check for potential debt spiral risks.

Net Debt-to-EBITDA

-1.53

Decreased from previous period

Net cash position while 3088.T shows net debt of 1.54. Joel Greenblatt would examine if this balance sheet advantage creates strategic opportunities.

Interest Coverage Ratio

46.19

Increased from previous period

Coverage 50-75% of 3088.T's 75.51. Bill Ackman would demand clear path to coverage improvement.

Current Ratio

0.90

Increased from previous period

Current ratio 75-90% of 3088.T's 1.08. Bruce Berkowitz would look for working capital optimization opportunities.

Intangibles-to-Total-Assets Ratio

0.66%

Increased from previous period

Intangibles less than half of 3088.T's 5.06%. Mohnish Pabrai would verify if this conservative approach sacrifices brand value opportunities.

Select Chart Metric:

3349.T Fundamental Risk Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Debt-to-Equity Ratio

0.50

Decreased from previous period

Dangerously higher D/E above 1.5x 3088.T's 0.24. Jim Chanos would check for potential debt spiral risks.

Net Debt-to-EBITDA

-1.53

Decreased from previous period

Net cash position while 3088.T shows net debt of 1.54. Joel Greenblatt would examine if this balance sheet advantage creates strategic opportunities.

Interest Coverage Ratio

46.19

Increased from previous period

Coverage 50-75% of 3088.T's 75.51. Bill Ackman would demand clear path to coverage improvement.

Current Ratio

0.90

Increased from previous period

Current ratio 75-90% of 3088.T's 1.08. Bruce Berkowitz would look for working capital optimization opportunities.

Intangibles-to-Total-Assets Ratio

0.66%

Increased from previous period

Intangibles less than half of 3088.T's 5.06%. Mohnish Pabrai would verify if this conservative approach sacrifices brand value opportunities.

Select Chart Metric: